Fig. 2.

Landscape of DNA mutations from EUS-FNAB-W. a: Distributions of the Variant Allele Frequency (VAF) of KRAS mutations in a retrospective series of punched surgical samples (left panel) and in each disease stage of EUS-FNAB-W from the BACAP protocol (right panel). VAF analysis was performed in a total of 345 patients (86.9% of cases). b: Oncoplot of the main mutations found by EUS-FNAB-W of the BACAP protocol. DNA sequencing was performed in a total of 390 patients (98.2% of cases). c: Proportion of patients presenting mutations in TP53 and RNF43 genes in each disease stage (R: resected and/or resectable; B: borderline; L.A.: locally advanced; M: metastatic). (Fisher’s exact test).